OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

Conference call begins at 4:30 p.m. Eastern time today Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial (NCT06655324). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerability in up to 200 healthy adults. Based on analysis of these results, Merck will determine whether and how to proceed with Phase 2 studies. ModeX continued to advance its immuno-oncolo ...